Medgenics Inc Presenting at ROTH Capital Growth Conference (5719B)
05 3월 2014 - 10:30PM
UK Regulatory
TIDMMEDG TIDMMEDU
RNS Number : 5719B
Medgenics Inc
05 March 2014
Press Release 5 March 2014
Medgenics, Inc. to Present at the 26(th) Annual
ROTH Capital Growth Conference
Medgenics, Inc. (NYSE MKT: MDGN) (AIM: MEDU, MEDG), the
developer of BioPump(TM) , a novel platform technology for the
sustained production and delivery of therapeutic proteins in
patients using ex-vivo gene therapy and their own tissue for the
treatment of rare and orphan diseases, today announced that Michael
Cola, President and CEO, will present a corporate overview at the
26(th) Annual ROTH Capital Growth Conference in Laguna Niguel on
Tuesday, March 11, 2014 at 8:00am PDT.
The presentation will not be webcast, but the slide presentation
will be available under 'Events' in the Investors section on the
Company's website at www.medgenics.com.
About Medgenics
Medgenics is developing and commercializing Biopump(TM), a
proprietary platform for the sustained production and delivery of
therapeutic proteins using ex-vivo gene therapy and the patient's
own tissue for the treatment of orphan and rare diseases. For more
information, visit the Company's website at www.medgenics.com.
Forward-looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and as that term is defined
in the Private Securities Litigation Reform Act of 1995, which
include all statements other than statements of historical fact,
including (without limitation) those regarding the Company's
financial position, its development and business strategy, its
product candidates and the plans and objectives of management for
future operations. The Company intends that such forward-looking
statements be subject to the safe harbors created by such laws.
Forward-looking statements are sometimes identified by their use of
the terms and phrases such as "estimate," "project," "intend, "
"forecast," "anticipate," "plan," "planning, "expect," "believe,"
"will," "will likely," "should," "could," "would," "may" or the
negative of such terms and other comparable terminology. All such
forward-looking statements are based on current expectations and
are subject to risks and uncertainties. Should any of these risks
or uncertainties materialize, or should any of the Company's
assumptions prove incorrect, actual results may differ materially
from those included within these forward-looking statements.
Accordingly, no undue reliance should be placed on these
forward-looking statements, which speak only as of the date made.
The Company expressly disclaims any obligation or undertaking to
disseminate any updates or revisions to any forward-looking
statements contained herein to reflect any change in the Company's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based.
As a result of these factors, the events described in the
forward-looking statements contained in this release may not
occur.
For further information, contact:
Medgenics, Inc.
John Leaman, CFO
john.leaman@medgenics.com
Stem Investor Relations Phone: +1 212 362 1200
Beth DelGiacco
beth@sternir.com
Abchurch Communications Phone: +44 207 398 7718
Joanne Shears / Jamie Hooper / Harriet
Rae
harriet.rae@abchurch-group.com
Oriel Securities (NOMAD & Broker) Phone: +44 207 710 7617
Jonathan Senior / Giles Balleny
- Ends -
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCGMGGFLKDGDZG
Medgenics(Regs) (LSE:MEDG)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Medgenics(Regs) (LSE:MEDG)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024